{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:56:41Z","timestamp":1789167401145,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Zur Therapie der Skabies kann orales Ivermectin eingesetzt werden. Die Evidenz f\u00fcr einen sicheren und wirksamen Einsatz bei Kleinkindern im Einzelheilversuch ist erarbeitet worden und publiziert. Um eine k\u00f6rpergewichtsadaptierte Dosierung auch f\u00fcr Kinder zu gew\u00e4hrleisten, wurde ein Ivermectin-haltiger Saft als Magistralrezeptur entwickelt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Da Ivermectin nicht als Reinsubstanz f\u00fcr die Rezeptur zur Verf\u00fcgung steht, wurden wirkstoffhaltige Tabletten als Ausgangsmaterial f\u00fcr die Entwicklung benutzt. Die Formulierung wurde entsprechend pharmazeutischer, regulatorischer und gebrauchsorientierter Kriterien konzipiert. Zum Nachweis der chemischen Stabilit\u00e4t wurde eine HPLC(Hochleistungsfl\u00fcssigkeitschromatographie)-Methode erarbeitet und validiert. Um die praktische Umsetzung zu erleichtern, wurden zudem Angaben zu geeigneten Packmitteln und zu Applikationshilfen erarbeitet, und die Rezeptur wurde taxiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Es konnte nachgewiesen werden, dass die finale Rezeptur stabil in der Apotheke hergestellt und \u00fcber 3\u00a0Wochen gelagert werden kann. Es haben sich keine Bedenken bez\u00fcglich der Vertr\u00e4glichkeit des Rezeptursaftes ergeben. Die physikochemischen Eigenschaften und der Geschmack der Rezeptur erm\u00f6glichen den beabsichtigten Gebrauch als gut dosierbaren Saft f\u00fcr Kinder.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Die entwickelte Rezeptur entspricht den Anforderungen der Apothekenbetriebsordnung (\u00a7\u00a07\u00a0ApBetrO) und erm\u00f6glicht eine exakte, k\u00f6rpergewichtsadaptierte Dosierung von oralem Ivermectin bei Kleinkindern. Untersuchungen zur Pharmakokinetik am Menschen bzw. klinische Studien zum Nachweis der Vertr\u00e4glichkeit und\/oder Wirksamkeit liegen f\u00fcr die Rezeptur nicht vor.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00105-021-04806-4","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T10:19:15Z","timestamp":1618309155000},"page":"720-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Entwicklung eines Ivermectin-haltigen Saftes als Magistralrezeptur f\u00fcr Kinder zur Therapie der Skabies","Development of an ivermectin-containing syrup as an extemporaneous preparation for treatment of scabies in children"],"prefix":"10.1007","volume":"72","author":[{"given":"Johannes","family":"Wohlrab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Stadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H. H.","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"4806_CR1","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/ddg.13130","volume":"14","author":"C Sunderk\u00f6tter","year":"2016","unstructured":"Sunderk\u00f6tter\u00a0C, Feldmeier\u00a0H, Folster-Holst\u00a0R et al (2016) S1 guidelines on the diagnosis and treatment of scabies\u2014short version. J\u00a0Dtsch Dermatol Ges 14:1155\u20131167","journal-title":"J Dtsch Dermatol Ges"},{"key":"4806_CR2","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/jamadermatol.2019.0279","volume":"155","author":"S Rosumeck","year":"2019","unstructured":"Rosumeck\u00a0S, Nast\u00a0A, Dressler\u00a0C (2019) Evaluation of ivermectin vs permethrin for treating scabies-summary of a\u00a0cochrane review. JAMA Dermatol 155:730\u2013732","journal-title":"JAMA Dermatol"},{"key":"4806_CR3","first-page":"15","volume":"17","author":"C Sunderk\u00f6tter","year":"2019","unstructured":"Sunderk\u00f6tter\u00a0C, Aebischer\u00a0A, Neufeld\u00a0M et\u00a0al (2019) Increase of scabies in Germany and development of resistant mites? Evidence and consequences. J\u00a0Dtsch Dermatol Ges 17:15\u201323","journal-title":"J Dtsch Dermatol Ges"},{"key":"4806_CR4","first-page":"554","volume":"18","author":"R Nemecek","year":"2020","unstructured":"Nemecek\u00a0R, Stockbauer\u00a0A, Lexa\u00a0M, Poeppl\u00a0W, Mooseder\u00a0G (2020) Application errors associated with topical treatment of scabies: an observational study. J\u00a0Dtsch Dermatol Ges 18:554\u2013559","journal-title":"J Dtsch Dermatol Ges"},{"key":"4806_CR5","doi-asserted-by":"publisher","first-page":"e0005920","DOI":"10.1371\/journal.pntd.0005920","volume":"11","author":"S Khalil","year":"2017","unstructured":"Khalil\u00a0S, Abbas\u00a0O, Kibbi\u00a0AG, Kurban\u00a0M (2017) Scabies in the age of increasing drug resistance. PLoS Negl Trop Dis 11:e5920","journal-title":"PLoS Negl Trop Dis"},{"key":"4806_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ad.2017.04.008","volume":"108","author":"G Blasco Morente","year":"2017","unstructured":"Blasco Morente\u00a0G (2017) Oral Ivermectin: regaining a\u00a0drug for the treatment of scabies. Actas Dermosifiliogr 108:606","journal-title":"Actas Dermosifiliogr"},{"key":"4806_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","volume":"33","author":"R Laing","year":"2017","unstructured":"Laing\u00a0R, Gillan\u00a0V, Devaney\u00a0E (2017) Ivermectin\u2014old drug, new tricks? Trends Parasitol 33:463\u2013472","journal-title":"Trends Parasitol"},{"key":"4806_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1746-6148-9-27","volume":"9","author":"G Suarez","year":"2013","unstructured":"Suarez\u00a0G, Alvarez\u00a0L, Castells\u00a0D et\u00a0al (2013) Relative bioavailability and comparative clinical efficacy of different ivermectin oral formulations in lambs. BMC Vet Res 9:27","journal-title":"BMC Vet Res"},{"key":"4806_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/inthealth\/ihz044","volume":"12","author":"JN Siewe Fodjo","year":"2020","unstructured":"Siewe Fodjo\u00a0JN, Mubiru\u00a0F, Ukaga\u00a0C et al (2020) Low ivermectin use among 5\u2011 to 6\u2011year-old children: observations from door-to-door surveys in onchocerciasis-endemic regions in Africa. Int Health 12:72\u201375","journal-title":"Int Health"},{"key":"4806_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/bjd.18788","volume":"182","author":"R Morris-Jones","year":"2020","unstructured":"Morris-Jones\u00a0R (2020) Oral ivermectin for infants and children under 15\u202fkg appears to be a\u00a0safe and effective treatment for scabies. Br J Dermatol 182:835\u2013836","journal-title":"Br J Dermatol"},{"key":"4806_CR11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/bjd.18369","volume":"182","author":"M Levy","year":"2020","unstructured":"Levy\u00a0M, Martin\u00a0L, Bursztejn\u00a0AC et\u00a0al (2020) Ivermectin safety in infants and children under 15\u202fkg treated for scabies: a\u00a0multicentric observational study. Br J Dermatol 182:1003\u20131006","journal-title":"Br J Dermatol"},{"key":"4806_CR12","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/bjd.18685","volume":"182","author":"R Colebunders","year":"2020","unstructured":"Colebunders\u00a0R, Wafula\u00a0ST, Hotterbeekx\u00a0A, Siewe-Fodjo\u00a0JN (2020) Ivermectin use in children below 15\u202fkg: potential benefits for onchocerciasis and scabies elimination programmes. Br J Dermatol 182:1064","journal-title":"Br J Dermatol"},{"key":"4806_CR13","first-page":"e736","volume":"34","author":"S Stander","year":"2020","unstructured":"Stander\u00a0S, Kirschstein\u00a0DJ, Kohl-Sobania\u00a0M et\u00a0al (2020) Effectiveness and adverse events of ivermectin treatment for scabies in 30 infant patients: report from a German single centre. J Eur Acad Dermatol Venereol 34:e736\u2013e737","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4806_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/BF02215150","volume":"9","author":"PK Lo","year":"1985","unstructured":"Lo\u00a0PK, Fink\u00a0DW, Williams\u00a0JB, Blodinger\u00a0J (1985) Pharmacokinetic studies of ivermectin: effects of formulation. Vet Res Commun 9:251\u2013268","journal-title":"Vet Res Commun"},{"key":"4806_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4155\/tde-2016-0067","volume":"8","author":"T Vasconcelos","year":"2017","unstructured":"Vasconcelos\u00a0T, Marques\u00a0S, Sarmento\u00a0B (2017) The biopharmaceutical classification system of excipients. Ther Deliv 8:65\u201378","journal-title":"Ther Deliv"},{"key":"4806_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2460\/ajvr.68.1.101","volume":"68","author":"AG Canga","year":"2007","unstructured":"Canga\u00a0AG, Sahagun\u00a0A, Diez\u00a0MJ et\u00a0al (2007) Bioavailability of a\u00a0commercial formulation of ivermectin after subcutaneous administration to sheep. Am J Vet Res 68:101\u2013106","journal-title":"Am J Vet Res"},{"key":"4806_CR17","unstructured":"United States Pharmacopeia. USP 36-NF 31. 2013."},{"key":"4806_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jpba.2018.12.030","volume":"165","author":"M Kaza","year":"2019","unstructured":"Kaza\u00a0M, Karazniewicz-Lada\u00a0M, Kosicka\u00a0K, Siemiatkowska\u00a0A, Rudzki\u00a0PJ (2019) Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse? J\u00a0Pharm Biomed Anal 165:381\u2013385","journal-title":"J Pharm Biomed Anal"},{"key":"4806_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.4155\/bio.09.94","volume":"1","author":"G Smith","year":"2009","unstructured":"Smith\u00a0G (2009) Review of the 2008 European Medicines Agency concept paper on bioanalytical method validation. Bioanalysis 1:877\u2013881","journal-title":"Bioanalysis"},{"key":"4806_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/2229-4708.72226","volume":"1","author":"G Tiwari","year":"2010","unstructured":"Tiwari\u00a0G, Tiwari\u00a0R (2010) Bioanalytical method validation: an updated review. Pharm Methods 1:25\u201338","journal-title":"Pharm Methods"},{"key":"4806_CR21","volume-title":"Bioanalytical method validation guidance for industry","author":"Food and Drug Administration","year":"2018","unstructured":"Food and Drug Administration (2018) Bioanalytical method validation guidance for industry"},{"key":"4806_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.4155\/bio.12.18","volume":"4","author":"M Boterman","year":"2012","unstructured":"Boterman\u00a0M, Doig\u00a0M, Breda\u00a0M et\u00a0al (2012) Recommendations on the interpretation of the new European Medicines Agency Guideline on Bioanalytical Method Validation by Global CRO Council for Bioanalysis (GCC). Bioanalysis 4:651\u2013660","journal-title":"Bioanalysis"},{"key":"4806_CR23","unstructured":"European Pharmacopoeia (Ph. Eur.). 10th Edition, 2020."},{"key":"4806_CR24","unstructured":"EMA-Committee for Medicinal Products for Human Use (2014) Guideline on stability testing for applications for variations to a\u00a0marketing authorisation. EMA\/CHMP\/CVMP\/QWP\/441071\/2011- Rev.2. Zugegriffen: 15.\u00a0Feb. 2021"},{"key":"4806_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0278-6915(85)90030-4","volume":"23","author":"NP Luepke","year":"1985","unstructured":"Luepke\u00a0NP (1985) Hen\u2019s egg chorioallantoic membrane test for irritation potential. Food Chem Toxicol 23:287\u2013291","journal-title":"Food Chem Toxicol"},{"key":"4806_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/0887-2333(93)90055-A","volume":"7","author":"H Spielmann","year":"1993","unstructured":"Spielmann\u00a0H, Kalweit\u00a0S, Liebsch\u00a0M et al (1993) Validation study of alternatives to the Draize eye irritation test in Germany: Cytotoxicity testing and HET-CAM test with 136 industrial chemicals. Toxicol In Vitro 7:505\u2013510","journal-title":"Toxicol In Vitro"},{"key":"4806_CR27","unstructured":"Interagency Coordinating Committee on the Validation of Alternative Methods (2010) ICCVAM-recommended test method protocol: hen\u2019s egg test\u2014chorioallantoic membrane (HET-CAM) test method. https:\/\/ntp.niehs.nih.gov\/iccvam\/docs\/protocols\/ivocular-hetcam.pdf. Zugegriffen: 15.\u00a0Feb. 2021"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04806-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04806-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04806-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T07:03:11Z","timestamp":1627542191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04806-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4806"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04806-4","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"11 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Wohlrab hat f\u00fcr Vortr\u00e4ge, Beratungsleistungen und anderweitige wissenschaftliche Projekte von der Firma InfectoPharm Arzneimittel und Consilium GmbH finanzielle Zuwendungen erhalten. L.\u00a0Stadie, R.H.H.\u00a0Neubert und K.\u00a0Bosse geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}